Terazosin: Difference between revisions
No edit summary |
|||
| Line 18: | Line 18: | ||
==FDA Package Insert== | ==FDA Package Insert== | ||
=== | ===Terazosin®=== | ||
''' [[Terazosin indications and usage|Indications and Usage]]''' | ''' [[Terazosin indications and usage|Indications and Usage]]''' | ||
'''| [[Terazosin dosage and administration|Dosage and Administration]]''' | '''| [[Terazosin dosage and administration|Dosage and Administration]]''' | ||
'''| [[Terazosin contraindications|Contraindications]]''' | '''| [[Terazosin contraindications|Contraindications]]''' | ||
'''| [[Terazosin warnings | '''| [[Terazosin warnings|Warnings]]''' | ||
'''| [[Terazosin precautions|Precautions]]''' | |||
'''| [[Terazosin adverse reactions|Adverse Reactions]]''' | '''| [[Terazosin adverse reactions|Adverse Reactions]]''' | ||
'''| [[Terazosin drug interactions|Drug Interactions]]''' | '''| [[Terazosin drug interactions|Drug Interactions]]''' | ||
| Line 33: | Line 33: | ||
'''| [[Terazosin clinical pharmacology|Clinical Pharmacology]]''' | '''| [[Terazosin clinical pharmacology|Clinical Pharmacology]]''' | ||
'''| [[Terazosin nonclinical toxicology|Nonclinical Toxicology]]''' | '''| [[Terazosin nonclinical toxicology|Nonclinical Toxicology]]''' | ||
'''| [[Terazosin how supplied storage and handling|How Supplied/Storage and Handling]]''' | '''| [[Terazosin how supplied storage and handling|How Supplied/Storage and Handling]]''' | ||
'''| [[Terazosin patient counseling information|Patient Counseling Information]]''' | '''| [[Terazosin patient counseling information|Patient Counseling Information]]''' | ||
Revision as of 19:25, 12 March 2014
| Terazosin |
|---|
| Terazosin®, Hytrin® FDA Package Insert |
| Indications and Usage |
| Dosage and Administration |
| Contraindications |
| Warnings |
| Precautions |
| Adverse Reactions |
| Drug Interactions |
| Use in Specific Populations |
| Overdosage |
| Description |
| Clinical Pharmacology |
| Nonclinical Toxicology |
| How Supplied/Storage and Handling |
| Patient Counseling Information |
| Labels and Packages |
| Clinical Trials on Terazosin |
| ClinicalTrials.gov |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
For patient information about Terazosin, click here.
Synonyms / Brand Names: Terazosin HCl, Terazosin hydrochloride, Terazosina, Terazosine, Terazosinum, Trazosin HCl, Abbott 45975, Blavin, Flumarc, Fosfomic, Heitrin, Hytracin, Hytrin, Hytrinex, Itrin, Urodie, Vasocard, Vasomet, Vicard
Overview
Terazosin (marketed as Hytrin or Zayasel) is a selective alpha 1 antagonist used for treatment of symptoms of an enlarged prostate (BPH). It also acts to lower the blood pressure, and is therefore a drug of choice for men with hypertension and prostate enlargement.
It works by blocking the action of adrenaline on smooth muscle of the bladder and the blood vessel walls.
Most common side effects include dizziness, drowsiness, headache, constipation, loss of appetite, fatigue, nasal congestion or dry eyes, but they generally go away after only a few days of use. Therapy should always be started with a low dose to avoid first dose phenomenon.[1] Sexual side effects are rare, but may include priapism or erectile dysfunction.
Category
Alpha adrenergic blockers.
FDA Package Insert
Terazosin®
Indications and Usage | Dosage and Administration | Contraindications | Warnings | Precautions | Adverse Reactions | Drug Interactions | Use in Specific Populations | Overdosage | Description | Clinical Pharmacology | Nonclinical Toxicology | How Supplied/Storage and Handling | Patient Counseling Information | Labels and Packages